Physician profile
Scott M Schlauder
NPI 1700030178
$961.88
in general payments reported to CMS, 2019-2025
13 companies · $423 in 2025
The $423 reported for 2025 was more than what 80% of Dermatopathology (Pathology) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.35 · 2020: $21.77 · 2021: $127 · 2022: $139 · 2023: $165 · 2024: $45.40 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $275.57 | 2022-2025 | Tremfya, Simponi, Remicade |
| Strata Skin Sciences, INC. | $158.59 | 2025 | Xtrac |
| Organogenesis INC. | $115.18 | 2021 | |
| Amgen INC. | $98.15 | 2022-2023 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $63.09 | 2022-2023 | Targretin, Siliq, Duobrii |
| Sun Pharmaceutical Industries INC. | $45.40 | 2024 | |
| Biofrontera INC. | $43.29 | 2020-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Pfizer INC. | $37.31 | 2019-2022 | |
| Elekta, INC. | $35.73 | 2025 | Flexitron Hdr |
| Abbvie INC. | $30.24 | 2021-2025 | |
| Leo Pharma INC. | $23.08 | 2019 | |
| Smith+Nephew, INC. | $19.47 | 2023 | Grafix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Schlauder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.